CSIMarket Company Name, Ticker, Customers, else..
 
Biostax Corp  (BTAX)
 
Price: $0.0002 $0.00 0.000%
Day's High: $0.00019999999494757503 Week Perf: 100 %
Day's Low: $ 0.00 30 Day Perf: 100 %
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 84
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Biostax Corp. is a pharmaceutical and biotechnology company engaged in acquiring, developing, and commercializing pharmaceutical and biotechnology products. The company advances small-scale biotechnology, pharmaceutical, and MedTech programs through subsidiaries, investment vehicles, and partnerships. It targets early-stage entrepreneurs, inventors, and universities to establish new companies based on their inventions. Key products include JKB-122 for autoimmune and liver diseases, Lodonal™ for HIV/AIDS treatment approved in Nigeria, and Low Dose Naltrexone (LDN) for immune modulation. The company plans to pursue regulatory approvals and commercialization in the U.S. and international markets.


   Company Address: 2774 East Colonial Dr Orlando 32803 FL
   Company Phone Number: 494-6875   Stock Exchange / Ticker: BTAX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        5.73% 
ABT   -3.31%    
BMY   -1.48%    
JNJ   -0.71%    
MRK   -3.15%    
PFE   -0.86%    
• View Complete Report
   



Stock Market Announcement

Strategic Delisting: Biostax Corp Moves to Strengthen Focus on Innovative Therapies Amid Shareholder Support

Published Fri, Feb 21 2025 2:00 PM UTC

Analysis of Biostax Corp s Strategic Delisting: Implications for Shareholders and Future DirectionsOn February 21, 2025, Biostax Corp (OTC Pink: BIOX), a biopharmaceutical entity devoted to pioneering immune restoration therapies, embarked on a significant strategic pivot by announcing its plan to voluntarily delist its common stock from the OTC Pink marketplace. The decisio...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0
Working Capital Ratio 0
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.02 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.